Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FOXK1 promotes nonalcoholic fatty liver disease by mediating mTORC1-dependent inhibition of hepatic fatty acid oxidation.
Fujinuma S, Nakatsumi H, Shimizu H, Sugiyama S, Harada A, Goya T, Tanaka M, Kohjima M, Takahashi M, Izumi Y, Yagi M, Kang D, Kaneko M, Shigeta M, Bamba T, Ohkawa Y, Nakayama KI. Fujinuma S, et al. Among authors: kohjima m. Cell Rep. 2023 May 30;42(5):112530. doi: 10.1016/j.celrep.2023.112530. Epub 2023 May 18. Cell Rep. 2023. PMID: 37209098 Free article.
Medium-chain fatty acids suppress lipotoxicity-induced hepatic fibrosis via the immunomodulating receptor GPR84.
Ohue-Kitano R, Nonaka H, Nishida A, Masujima Y, Takahashi D, Ikeda T, Uwamizu A, Tanaka M, Kohjima M, Igarashi M, Katoh H, Tanaka T, Inoue A, Suganami T, Hase K, Ogawa Y, Aoki J, Kimura I. Ohue-Kitano R, et al. Among authors: kohjima m. JCI Insight. 2023 Jan 24;8(2):e165469. doi: 10.1172/jci.insight.165469. JCI Insight. 2023. PMID: 36480287 Free PMC article.
Microcirculatory disturbance in acute liver injury is triggered by IFNγ-CD40 axis.
Kurokawa M, Goya T, Kohjima M, Tanaka M, Iwabuchi S, Shichino S, Ueha S, Hioki T, Aoyagi T, Takahashi M, Imoto K, Tashiro S, Suzuki H, Kato M, Hashimoto S, Matsuda H, Matsushima K, Ogawa Y. Kurokawa M, et al. Among authors: kohjima m. J Inflamm (Lond). 2024 Jun 21;21(1):23. doi: 10.1186/s12950-024-00387-w. J Inflamm (Lond). 2024. PMID: 38907339 Free PMC article.
ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.
Atsukawa M, Tsubota A, Kondo C, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Morishita A, Tani J, Okubo H, Hiraoka A, Nozaki A, Chuma M, Kawata K, Uojima H, Ogawa C, Asano T, Mikami S, Kato K, Matsuura K, Ikegami T, Ishikawa T, Tsuji K, Tada T, Tsutsui A, Senoh T, Kitamura M, Okubo T, Arai T, Kohjima M, Morita K, Akahane T, Nishikawa H, Iwasa M, Tanaka Y, Iwakiri K. Atsukawa M, et al. Among authors: kohjima m. J Gastroenterol. 2024 Aug;59(8):709-718. doi: 10.1007/s00535-024-02109-8. Epub 2024 May 10. J Gastroenterol. 2024. PMID: 38727822
Transcatheter arterial steroid injection therapy improves the prognosis of patients with acute liver failure.
Kuwano A, Okui T, Kohjima M, Kurokawa M, Goya T, Tanaka M, Aoyagi T, Takahashi M, Imoto K, Tashiro S, Suzuki H, Fujita N, Ushijima Y, Ishigami K, Tokunaga S, Kato M, Ogawa Y. Kuwano A, et al. Among authors: kohjima m. Medicine (Baltimore). 2023 Mar 10;102(10):e33090. doi: 10.1097/MD.0000000000033090. Medicine (Baltimore). 2023. PMID: 36897684 Free PMC article.
Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma.
Sugimoto R, Motomura K, Ooho A, Aratake Y, Ueda A, Senju T, Tanaka Y, Yada M, Tanaka K, Kuwano A, Morita Y, Nagasawa S, Ooe M, Mutsuki T, Yoshimoto T, Yamashita N, Nakashima M, Hioki T, Koyanagi T, Higuchi N, Nakamura T, Harada S, Tanaka M, Tada S, Satoh T, Uchimura K, Kuniyoshi M, Nakamuta M, Kohjima M; Liver Disease Investigators' Network of Kyushu University & Surrounding Hospitals (LINKS). Sugimoto R, et al. Among authors: kohjima m. Intern Med. 2022;61(21):3157-3164. doi: 10.2169/internalmedicine.9237-21. Epub 2022 Nov 1. Intern Med. 2022. PMID: 36328582 Free PMC article.
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study.
Sugimoto R, Satoh T, Ueda A, Senju T, Tanaka Y, Yamashita S, Koyanagi T, Kurashige T, Higuchi N, Nakamura T, Tanaka M, Azuma Y, Ohno A, Ooho A, Ooe M, Mutsuki T, Uchimura K, Kuniyoshi M, Tada S, Aratake Y, Yoshimoto T, Yamashita N, Harada S, Nakamuta M, Motomura K, Kohjima M; Liver disease Investigators’ Network of Kyushu University & Surrounding Hospitals (LINKS). Sugimoto R, et al. Among authors: kohjima m. Medicine (Baltimore). 2022 Oct 7;101(40):e30871. doi: 10.1097/MD.0000000000030871. Medicine (Baltimore). 2022. PMID: 36221372 Free PMC article.
115 results